These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 1947794)

  • 21. Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.
    Ramadass M; Ghebrehiwet B; Kew RR
    Mol Immunol; 2015 Mar; 64(1):55-62. PubMed ID: 25466612
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Medicus RG; Melamed J; Arnaout MA
    Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Processing and presentation of tetanus toxin by antigen-presenting cells from patients with chronic granulomatous disease (CGD) to human specific T cell clones are not impaired.
    Barbey C; Tiercy JM; Fairweather N; Niemann H; Seger R; Corradin G
    Clin Exp Immunol; 1994 Feb; 95(2):227-31. PubMed ID: 8306496
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine is a potential site for covalent attachment of activated complement component C3.
    Sahu A; Pangburn MK
    Mol Immunol; 1995 Jul; 32(10):711-6. PubMed ID: 7659097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b.
    Sahu A; Rawal N; Pangburn MK
    Biochem Pharmacol; 1999 Jun; 57(12):1439-46. PubMed ID: 10353266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of cellular Fc and C3 receptors on the complement-dependent degradation of stable soluble immunoglobulin aggregates by normal and trypsin-treated peritoneal macrophages.
    Daha MR; van Es LA
    Immunology; 1982 Sep; 47(1):203-9. PubMed ID: 7118161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of complement fragments C3b and C3a from purified rat complement component C3 by activated cobra venom factor.
    Usami M; Ohno Y
    J Pharmacol Toxicol Methods; 2005; 52(2):260-3. PubMed ID: 16125624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third component of complement (C3): structural properties in relation to functions.
    Bokisch VA; Dierich MP; Mūller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1975 Jun; 72(6):1989-93. PubMed ID: 1056006
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited tryptic cleavage of complement factor H abrogates recognition of sialic acid-containing surfaces by the alternative pathway of complement.
    Koistinen V
    Biochem J; 1992 Apr; 283 ( Pt 2)(Pt 2):317-9. PubMed ID: 1533511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improvement of long-lasting response and antibody affinity by the complexation of antigen with complement C3b.
    Villiers MB; Marche PN; Villiers CL
    Int Immunol; 2003 Jan; 15(1):91-5. PubMed ID: 12502729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes.
    Fries LF; Siwik SA; Malbran A; Frank MM
    Immunology; 1987 Sep; 62(1):45-51. PubMed ID: 3653927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement receptor binding of C3b-coated cells treated with C3b inactivator, beta 1H globulin and trypsin.
    Carlo JR; Ruddy S; Studer EJ; Conrad DH
    J Immunol; 1979 Aug; 123(2):523-8. PubMed ID: 88474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The third component of complement: covalent attachment of a radioactive sugar to the labile binding site of C3 via the alternative pathway.
    Mann J; O'Brien R; Hostetter MK; Alper CA; Rosen FS; Babior BM
    J Immunol; 1981 Jun; 126(6):2370-2. PubMed ID: 6785350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes.
    Edberg JC; Tosic L; Wright EL; Sutherland WM; Taylor RP
    J Immunol; 1988 Dec; 141(12):4258-65. PubMed ID: 3198918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.